19 October 2026 : Clinical Research
[In Press] Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response of Hepatocellular Carcinoma: Single-Center Development and Korea-Nationwide Multi-Center Validation Studies
Woo-Hyoung KangDOI: 10.12659/AOT.954574
Ann Transplant In Press; DOI: 10.12659/AOT.954574
Available online: 2026-10-19, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Complete pathological response (CPR) after locoregional treatments (LRTs) predicts better outcomes in patients with hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). This study aimed to find risk factors associated with HCC recurrence in patients with LRT-induced CPR of HCC.
MATERIAL AND METHODS
Prognostic factors were identified from a development cohort of 313 patients from a high-volume single-center LDLT database and validated using a nationwide cohort of 418 patients from the Korean multi-center transplantation registry.
RESULTS
In the development study, 380 LRT sessions were performed on 313 patients, while the validation study included 482 sessions for 418 patients. Cumulative tumor recurrence and overall survival rates in the development study showed recurrence rates of 2.0%, 3.9%, 3.9%, and 4.5% and overall survival rates of 97.1%, 93.5%, 91.4%, and 89.2% at 1, 3, 5, and 10 years, respectively, respectively. In the validation study, tumor recurrence rates were 3.4%, 5.6%, and 7.7%, and overall survival rates were 98.6%, 96.0%, and 93.5% at 1, 3, and 5 years, respectively. Multiplicity of non-viable tumors was identified as a significant risk factor for tumor recurrence (P=0.001; HR=9.83) and overall survival (P=0.021; HR=2.91) in the development study, whereas the composite AFP–PIVKA-II score did not show significance. The validation study confirmed that the multiplicity of non-viable tumors was the only significant risk factor for tumor recurrence (P=0.026; HR=2.47) and overall survival (P=0.017; HR=2.82).
CONCLUSIONS
This study demonstrates that LDLT recipients exhibiting LRT-induced CPR with multiple non-viable tumors constitute a high-risk subgroup and may require intensive posttransplant surveillance.
Keywords: Carcinoma, Hepatocellular; Necrosis; Recurrence; Response Evaluation Criteria in Solid Tumors; Transplantation
In Press
Original article
Analysis of Factors Influencing the Psychological State of Patients After Autologous Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.953645
Original article
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...Ann Transplant In Press; DOI: 10.12659/AOT.953761
Clinical Research
Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cel...Ann Transplant In Press; DOI: 10.12659/AOT.954230
Clinical Research
Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response ...Ann Transplant In Press; DOI: 10.12659/AOT.954574
Most Viewed Current Articles
24 Aug 2021 : Review article 21,930
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 18,183
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,833
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,744
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






